Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.doi:10.3371/CSRP.KEBE.070415Deanna L. KellyHadar Ben-YoavGregory F. PayneThomas E. WinklerSheryl E. ChocronEunkyoung KimChristopher Kitchen
Because of its possible severe side effects, including granulocytopenia or even agranulocytosis, clozapine treatment entails regular WBC monitoring, which can be a major drawback for patients and practitioners. The HemoCue WBC DIFF system is a point-of-care device using capillary blood sampling ...